CD28 costimulator bispecific antibody (Regeneron Pharmaceuticals)

N/A

Report date: 2026/03/19 16:59:28

Base Information

Drug NameCD28 costimulator bispecific antibody (Regeneron Pharmaceuticals)
Drug Alias Namedual plasma cell tumor antigen/CD28 costimulator (Regeneron Pharmaceuticals)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionLymphocyte differentiation antigen CD38 inhibitorsT-cell-specific surface glycoprotein CD28 agonists
TargetsLymphocyte differentiation antigen CD38T-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A